분화성갑상선암에서 최초 고용량 방사성요오드 치료시 혈청 갑상선글로불린 수치 변화의 의의 = Value of the Serum Thyroglobulin Level Alteration at the First High Dose Radioiodine Treatment in Patients with Differentiated Thyroid Carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited between a group administered with recombinant human thyrotropin (rhTSH) and a group experiencing thyroid hormone withdrawal (THW), in preparation for RRA. Materials and Methods: A retrospective chart review was performed on 39 patients in the rhTSH group and 46 patients in the THW group. They were treated for differentiated thyroid carcinoma by total or near total thyroidectomy, and referred for RRA between 2003 and 2006 (the rhTSH group) and between January and June of 2006 (the THW group). They were assessed for serum Tg levels just before I-131 administration (TgD0), reassessed 9 days later (TgD9), and again 6-12 months later. Results: RRA was successful in 64 (37 from the THW group and 27 from the rhTSH group) of the total 85 patients. The success rates of RRA had no statistically significant differences between the two groups. In both groups, TgD9/TgD0 values were significantly higher in the RRA success group (the rhTSH group; P=0.03, the THW group; P=0.04). By combining cutoff values of TgD0 and TgD9/TgD0, the successful RRA value was determined to be 96.7% (29/30) with TgD0≤5.28 ng/mL and TgD9/TgD0>4.37 in both groups (the rhTSH group; 100% (16/16), the THW group; 92.9% (13/14)). Using logistic multivariate analysis, only TgD0 was independently associated with successful RRA. Conclusion: We may predict successful ablation by evaluating short-term serum Tg elevation after I-131 administration for RRA, in both rhTSH and THW patients. (Nucl Med Mol Imaging 2009;43(4):294-300)

참고문헌 (Reference)

1 Menzel C, "rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I" 44 : 1065-1068, 2003

2 Ronga G, "Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma" 26 : 1448-1452, 1999

3 Giovanella L, "Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures" 44 : 648-652, 2006

4 Torrens J, "Serum thyroglobulin measurement: Utility in clinical practice" 30 : 1-34, 2001

5 Tuttle RM, "Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal" 49 : 764-770, 2008

6 Cramp WA, "Recent developments in the radiobiology of cellular membranes" 33 : 945-952, 1994

7 Sweeney DC, "Radioiodine therapy for thyroid cancer" 24 : 803-839, 1995

8 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 : 926-932, 2006

9 Crevenna R, "Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy" 11 : 597-603, 2003

10 Dow KH, "Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy" 7 : 613-619, 1997

11 Botella-Carretero JI, "Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma" 10 : 601-610, 2003

12 Lima N, "Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer" 25 : 110-115, 2002

13 Bernier MO, "Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer" 32 : 1418-1421, 2005

14 Lee HJ, "Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma" 30 : 63-68, 2007

15 Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer" 45 : 988-994, 2004

16 Arslan N, "Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma" 22 : 1021-1027, 2001

17 Sugino K, "Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH" 53 : 723-728, 2006

18 Karam M, "Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates" 24 : 489-495, 2003

19 Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer" 35 : 1941-1959, 2008

20 Schlumberger M, "Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice" 151 : 539-548, 2004

21 Rosario PW, "Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays?" 68 : 338-342, 2008

22 Sawka AM, "Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer" 89 : 3668-3676, 2004

23 Robbins RJ, "Clinical review 156: recombinant human thyrotropin and thyroid cancer management" 88 : 1933-1938, 2003

24 Mazzaferri EL, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer" 86 : 1447-1463, 2001

25 Mazzaferri EL, "An overview of the management of papillary and follicular thyroid carcinoma" 9 : 421-427, 1999

26 Schroeder PR, "A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal" 91 : 878-894, 2006